Dyslipidemia treatment represents a very dynamically growing segment of pharmacotherapy, including a production of biological agents. Nowadays, they are targeting at various proteins that are involved in the synthesis, transport, or metabolism of lipoproteins. This review provides a statement of current options for the biological treatment of dyslipidemias and for other products that have the potential to broaden its spectrum in the near future.
Keywords: APO(a)-LRx; PCSK9-inhibitors; evinacumab; inclisiran; mipomersen; mixed dyslipidemia; volanesorsen.